Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2021 - 2040

GISAR - REGISTER (#1316)
  • Dr. MariusFried,
  • Prof. Dr. ThomasKindler,
  • SergioZapata Bonilla

2021 - 2026

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
  • Prof. Dr. med. GeorgHeß

2021 - 2040

MORNING (#1317)
  • Dr. MariusFried,
  • SergioZapata Bonilla

2021 - 2027

A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.
  • MariusFried,
  • Dr. med. Alexander Desuki

2021 - 2027

Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER®), in patients with recurrent and/or refractory solid tumors
  • MariusFried,
  • Dr. med. Alexander Desuki

2021 - 2040

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (#1397)
  • Dr. DanielSasca

2021 - 2023

Utilization of the HLA-independent anti-tumor T-cell repertoire for cancer immunotherapy
  • Univ.-Prof. Dr. ThomasWölfel

2021 - 2023

MORE – Molecular Mechanisms of Resilience
  • Univ.-Prof. Dr. ChristophReinhardt

2021 - 2025

SFB 1292/Teilprojekt 12
  • Dr. MichaelKühn,
  • Prof. Dr. EvelynUllrich

2021 - 2040

Sicherheit, Verträglichkeit und Machbarkeit der Behandlung mit GP120-aktivierten regulatorischen T-Zellen (ATreg) frühzeitig nach hämatopoetischer Stammzelltransplantation (HSCT) zur Verringerung der Inzidenz und des Schweregrades der akuten Graft vs. Host Disease (GvHD) (ATreg-001) (#1423)
  • Dr. Eva MariaWagner-Drouet